Account
Poster
15.10.2025
What Are the Likely PICOs for Tovorafenib and Lifi...

Objectives:  ​​EUHTA regulation has applied from the 1st January 2025 for oncology pr...

Read more
Poster
15.10.2025
How the EU JCA could interface with Regional Prici...

Objectives: ​​To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...

Read more
Articles
08.09.2025
The JCA is here – are you generating the right e...

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu...

Read more
Articles
11.08.2025
Why your PICO strategy matters to successful JCA 

The Joint Clinical Assessment (JCA), a core feature of the Regulation (EU) 2021/2282, aims to stream...

Read more
Webinar
07.11.2024
Breaking new ground: key learnings from one of the...

Remap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...

Read more
News
29.08.2024
ISPOR Europe 2024

We're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Alignment of EU HTA and member ...

We examine whether the joint clinical assessment will expedite patient access and influence value pe...

Read more
Articles
20.08.2024
Adapting to the EU HTA: how to restructure your Ma...

Our latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...

Read more
16.07.2024
Joint Nordic HTA Bodies produce draft process guid...

The collaboration is aimed at enhancing HTA reports, facilitating resource and knowledge sharing and...

Read more
News
18.06.2024
HTAi Annual Meeting 2024

We summarise the key discussions from HTAi 2024, with a focus on sustainability, networks and innova...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.